Renal Anemia Clinical Trial
Official title:
The Association Between the Distributions MCH and RBC, and Mortality in a Cohort of Chronic Hemodialysis Patients: a 3-year Retrospective Observational Study
NCT number | NCT04227158 |
Other study ID # | Uhyogo4 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | April 20, 2020 |
Est. completion date | August 20, 2020 |
Verified date | March 2020 |
Source | University of Hyogo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Patients were classified into two groups based on the values of MCH and RBC, patients with MCH ≥30 pg but <35 pg and RBC ≤350×104/μL; and MCH <30 pg and RBC >350×104/μL. Associations between all-cause mortality and the distributions of MCH and RBC were assessed by Kaplan-Meier curves and Cox proportional hazards regression model.
Status | Completed |
Enrollment | 437 |
Est. completion date | August 20, 2020 |
Est. primary completion date | August 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 90 Years |
Eligibility | Inclusion Criteria: - Patients will be controlled with hemoglobin levels between =10 g/dL and <12 g/dL and had undergone maintenance HD for >1 year. Exclusion Criteria: - Patients will be excluded if they have peritoneal dialysis combined with HD, do not have records of laboratory investigations during this period, or are transferred to another hospital or lost to follow-up. |
Country | Name | City | State |
---|---|---|---|
Japan | Graduate School of Applied Informatics, University of Hyogo | Kobe | Hyogo |
Lead Sponsor | Collaborator |
---|---|
University of Hyogo |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival rate between high or low RBC group (all cause death) | Survival curves for 3-year survival, based on all available follow-up data, will perform with the use of Kaplan-Meier estimates and will be compared between groups with the use of the log-rank test, and used Holm's method as post hoc. | three years (retrospectively) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Active, not recruiting |
NCT03388385 -
Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD
|
Phase 4 | |
Completed |
NCT05035641 -
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
|
Phase 2 | |
Completed |
NCT02299661 -
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
|
Phase 1 | |
Active, not recruiting |
NCT05265325 -
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
|
Phase 2 | |
Completed |
NCT05864261 -
Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers
|
Phase 4 | |
Active, not recruiting |
NCT05085275 -
Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02708914 -
Study to Compare the Safety and Efficacy of UB-851 and Eprex®
|
Phase 3 | |
Completed |
NCT02041208 -
Variability of Hemoglobin Levels After Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT04775615 -
Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.
|
Phase 1 | |
Completed |
NCT00298441 -
Efficacy of Intravenous Iron Administration in Hemodialysis Patients
|
Phase 4 | |
Active, not recruiting |
NCT04408820 -
Post-marketing Surveillance of EVRENZO® Tablets (Roxadustat) in Patients With Renal Anemia
|
||
Completed |
NCT01543477 -
Post-Authorisation Safety Cohort Observation of RetacritTM (Epoetin Zeta) Administered Subcutaneously for the Treatment of Renal Anaemia
|
||
Completed |
NCT05951192 -
A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease
|
Phase 4 | |
Completed |
NCT04454879 -
Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients
|
Phase 4 | |
Recruiting |
NCT04360902 -
Assessment of an Anemia Model Predictive Controller for Anemia Management in Hemodialysis Patients
|
N/A | |
Not yet recruiting |
NCT03480178 -
Renal Anemia Refractory to Erythropoietin
|
||
Completed |
NCT01306409 -
Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)
|
Phase 4 | |
Completed |
NCT00322413 -
Comparison of Epoetin Alfa and Epoetin Omega in Anemic Dialysis Patients:Results of Efficacy Trial
|
Phase 3 | |
Recruiting |
NCT05970172 -
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
|
Phase 3 |